Clinical Trial Update: DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of DS-1205c combined with osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DS-1205c (DS-1205c)
• Osimertinib (osimertinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Status: TERMINATED | Results posted: 2022-01-11